feed,title,long_url,short_url
r/science:15+,"[Cancer] First-in-class bifunctional TCR-targeting antibody fusion molecule boosts antitumor T cell responses. Currently, treatment of solid tumors with T cell-directed therapies has limitations, and most patients fail to respond or progress after checkpoint inhibitor treatment.",https://redd.it/18anmxu,
